ReviewCancer letters2017
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.
Review in Cancer letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review.Current cancer drug targets · 2025Pooled it
- Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clinical and molecular hepatology · 2026Review
- Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma.Cancers · 2024Review
- Review
- Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.Journal of hematology & oncology · 2024Review
- Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.Journal of clinical and translational hepatology · 2024Review
- Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.World journal of gastroenterology · 2023Review
- Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.Frontiers in immunology · 2023Review
- Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Review
- Editorial: Organoids, organs-on-chip, nanoparticles andFrontiers in immunology · 2023Article
- Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors.Frontiers in oncology · 2023Article
- Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.Frontiers in oncology · 2022Review
- The Immunology of Hepatocellular Carcinoma.Vaccines · 2021Review
- A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment.Biomedicines · 2021Review
- Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.Frontiers in immunology · 2021Review
- Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.Cellular & molecular immunology · 2020Review
- Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.Journal of clinical medicine · 2020Review
- Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release.Therapeutic advances in medical oncology · 2020Article
- The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide with an overall survival rate of less than 15% in developed countries. Despite attempts at new therapeutic strategies, the majority of patients succumb to this cancer. Buttressed by the highly successful clinical impact in melanoma, immunotherapy is gaining momentum as the next treatment modality for many human cancers. Chimeric antigen receptors (CAR) contain the antigen binding moieties of a monoclonal antibody and the co-stimulatory and signaling domains associated with effector receptor signaling. Bispecific antibodies (BsAb) combine the binding specificities of two different monoclonal antibodies, one activating a receptor on a killer effector cell, while the other engaging a tumor-associated antigen to initiate tumor cytotoxicity. In this review, we survey the HCC targets for which CARs and bispecific antibodies have been generated. The pros and cons of these targets for T-cell and Natural Killer cell based immunotherapy will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.